HuidaGene Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A gene-editing biotech creating CRISPR-based therapies for genetic diseases.
Genetics & GenomicsOphthalmologyMetabolic
Technology Platform
A proprietary gene-editing platform based on novel CRISPR systems and delivery technologies designed for precise in vivo genome modification.
Opportunities
Potential to develop one-time curative treatments for severe genetic diseases, commanding high value and transforming patient care.
Risk Factors
Faces substantial scientific risks related to off-target editing effects, immune responses, and long-term safety of gene therapies.
Competitive Landscape
Operates in the highly competitive and capital-intensive global gene editing arena, competing on technology differentiation, IP, and clinical execution.